Katherine Mackey1, Stephanie Veazie2, Johanna Anderson2, Donald Bourne2, Kim Peterson2. 1. Evidence Synthesis Program (ESP) Coordinating Center, VA Portland Health Care System, Portland, OR, USA. katherine.mackey@va.gov. 2. Evidence Synthesis Program (ESP) Coordinating Center, VA Portland Health Care System, Portland, OR, USA.
Abstract
BACKGROUND: Despite evidence that medications to treat opioid use disorder (OUD) are effective, most people who could benefit from this treatment do not receive it. This rapid review synthesizes evidence on current barriers and facilitators to buprenorphine/naloxone and naltrexone at the patient, provider, and system levels to inform future interventions aimed at expanding treatment. METHODS: We systematically searched numerous bibliographic databases through May 2020 and selected studies published since 2014. Study selection, data abstraction, coding of barriers and facilitators, and quality assessment were first completed by one reviewer and checked by a second. RESULTS: We included 40 studies of buprenorphine (5 also discussed naltrexone). Four types of patient and provider-level barriers to OUD medication use emerged-stigma related to OUD medications, treatment experiences and beliefs (positive or negative), logistical issues (time and costs as well as insurance and regulatory requirements), and knowledge (high or low) of OUD and the role of medications. Stigma was the most common barrier among patients, while logistical issues were the most common barriers among providers. Facilitators for both patients and providers included peer supports. Most administrator-identified or system-level barriers and facilitators fit into the category of logistical issues. We have moderate confidence in buprenorphine findings but low confidence in naltrexone findings due to the small number of studies. DISCUSSION: Stigma, treatment experiences, logistical issues, and knowledge gaps are the main barriers associated with low utilization of OUD medications. These barriers can overlap and mutually reinforce each other, but given that, it is plausible that reducing one barrier may lead to reductions in others. The highest priority for future research is to evaluate interventions to reduce stigma. Other priorities for future research include better identification of barriers and facilitators for specific populations, such as those with OUD related to prescription opioids, and for naltrexone use. PROTOCOL REGISTRATION: PROSPERO; CRD42019133394.
BACKGROUND: Despite evidence that medications to treat opioid use disorder (OUD) are effective, most people who could benefit from this treatment do not receive it. This rapid review synthesizes evidence on current barriers and facilitators to buprenorphine/naloxone and naltrexone at the patient, provider, and system levels to inform future interventions aimed at expanding treatment. METHODS: We systematically searched numerous bibliographic databases through May 2020 and selected studies published since 2014. Study selection, data abstraction, coding of barriers and facilitators, and quality assessment were first completed by one reviewer and checked by a second. RESULTS: We included 40 studies of buprenorphine (5 also discussed naltrexone). Four types of patient and provider-level barriers to OUD medication use emerged-stigma related to OUD medications, treatment experiences and beliefs (positive or negative), logistical issues (time and costs as well as insurance and regulatory requirements), and knowledge (high or low) of OUD and the role of medications. Stigma was the most common barrier among patients, while logistical issues were the most common barriers among providers. Facilitators for both patients and providers included peer supports. Most administrator-identified or system-level barriers and facilitators fit into the category of logistical issues. We have moderate confidence in buprenorphine findings but low confidence in naltrexone findings due to the small number of studies. DISCUSSION: Stigma, treatment experiences, logistical issues, and knowledge gaps are the main barriers associated with low utilization of OUD medications. These barriers can overlap and mutually reinforce each other, but given that, it is plausible that reducing one barrier may lead to reductions in others. The highest priority for future research is to evaluate interventions to reduce stigma. Other priorities for future research include better identification of barriers and facilitators for specific populations, such as those with OUD related to prescription opioids, and for naltrexone use. PROTOCOL REGISTRATION: PROSPERO; CRD42019133394.
Entities:
Keywords:
barriers; buprenorphine; facilitators; naltrexone; opioid use disorder
Authors: Claire B Simon; Judith I Tsui; Joseph O Merrill; Addy Adwell; Elsa Tamru; Jared W Klein Journal: Drug Alcohol Depend Date: 2017-10-10 Impact factor: 4.492
Authors: Nicole Brunet; David T Moore; Dora Lendvai Wischik; Kristin M Mattocks; Marc I Rosen Journal: Subst Abus Date: 2020-02-20 Impact factor: 3.984
Authors: Hannah Lf Cooper; David H Cloud; Patricia R Freeman; Monica Fadanelli; Travis Green; Connor Van Meter; Stephanie Beane; Umedjon Ibragimov; April M Young Journal: Int J Drug Policy Date: 2020-03-26
Authors: Rachel M Burns; Rosalie L Pacula; Sebastian Bauhoff; Adam J Gordon; Hollie Hendrikson; Douglas L Leslie; Bradley D Stein Journal: Subst Abus Date: 2015-11-13 Impact factor: 3.716
Authors: Dana D Im; Anita Chary; Anna L Condella; Hurnan Vongsachang; Lucas C Carlson; Lara Vogel; Alister Martin; Nathan Kunzler; Scott G Weiner; Margaret Samuels-Kalow Journal: West J Emerg Med Date: 2020-02-21
Authors: Margaret Lowenstein; Jeanmarie Perrone; Ruiying A Xiong; Christopher K Snider; Nicole O'Donnell; Davis Hermann; Roy Rosin; Julie Dees; Rachel McFadden; Utsha Khatri; Zachary F Meisel; Nandita Mitra; M Kit Delgado Journal: Ann Emerg Med Date: 2021-12-23 Impact factor: 5.721
Authors: Gian-Gabriel P Garcia; Ramin Dehghanpoor; Erin J Stringfellow; Marichi Gupta; Jillian Rochelle; Elizabeth Mason; Toyya A Pujol; Mohammad S Jalali Journal: Int J Environ Res Public Health Date: 2022-05-22 Impact factor: 4.614
Authors: Margarita Alegría; Irene Falgas-Bague; Marie Fukuda; Jenny Zhen-Duan; Cole Weaver; Isabel O'Malley; Timothy Layton; Jacob Wallace; Lulu Zhang; Sheri Markle; Charles Neighbors; Pat Lincourt; Shazia Hussain; Marc Manseau; Bradley D Stein; Nancy Rigotti; Sarah Wakeman; Martha Kane; A Eden Evins; Thomas McGuire Journal: JAMA Health Forum Date: 2022-07-01
Authors: Julia Dickson-Gomez; Antoinette Spector; Margaret Weeks; Carol Galletly; Madelyn McDonald; Helena Danielle Green Montaque Journal: Subst Abuse Date: 2022-06-27
Authors: Jayamalathi Priyanka Vakkalanka; Brian C Lund; Stephan Arndt; William Field; Mary Charlton; Marcia M Ward; Ryan M Carnahan Journal: Health Serv Res Date: 2021-12-18 Impact factor: 3.734
Authors: Erica Morse; Ingrid A Binswanger; Emmeline Taylor; Caroline Gray; Matthew Stimmel; Christine Timko; Alex H S Harris; David Smelson; Andrea K Finlay Journal: J Subst Abuse Treat Date: 2021-03-04